Effects of OPG-Fc or zoledronate on the number of channels in the osteochondral junction (OCJ) in the medial tibial plateaus (MTPs), chondrocyte appearance and proteoglycan loss in MIA-treated rats compared with MIA-vehicle-treated and saline-treated rats.
| Pre-emptive OPG | Therapeutic OPG | Pre-emptive zoledronate | ||||||
|---|---|---|---|---|---|---|---|---|
| Saline-vehicle | MIA-vehicle | MIA-OPG | MIA-vehicle | MIA-OPG | Saline-vehicle | MIA-vehicle | MIA-zoledronate | |
| Number of channels crossing the OCJ in MTP | 4±0.4 | 8±1 | 7±2 | 7±1 | 6±0.4 | 1±0.3 | 7±1*** | 3±0.6*+ |
| Chondrocyte appearance score | 0.3±0.2 | 2±0.3** | 3±0.2*** | 3±0.3 | 2±0.3 | 0±0 | 3±0*** | 3±0.2*** |
| Proteoglycan loss grade | 1.2±0.3 | 3±0.4* | 3±0.3* | 4±0 | 4±0 | 0.3±0.2 | 4±0.2*** | 3±0.2*** |
Statistical analysis was performed with a Kruskal–Wallis test.
*p<0.05, **p<0.01, ***p<0.001 versus saline-vehicle; +p<0.05 versus MIA-vehicle.
Data are expressed as mean±SEM per section.
MIA, monosodium iodoacetate; OPG, osteoprotegerin.